Analyst consensus ratings for AstraZeneca (commonly tracked under the ticker AZN) generally lean toward a strong buy or moderate buy consensus, supported by institutional confidence in its robust oncology drug pipeline, rare disease portfolio, and expanding metabolic treatments. Wall Street equity researchers regularly update their target valuations based on clinical trial milestones, regulatory approvals, and quarterly earnings performance, advising investors to weigh long-term growth against sector-specific regulatory risks.